(Q41692606)

7 October 2017

title

Daclizumab: novel biologic immunoprophylaxis for prevention of acute rejection in renal transplantation (English)

1 reference

7 October 2017

Vincenti F

1

1 reference

7 October 2017

language of work or name

English

0 references

publication date

1 September 1999

1 reference

Transplantation Proceedings

7 October 2017

published in

1 reference

7 October 2017

volume

31

1 reference

7 October 2017

issue

6

1 reference

7 October 2017

page(s)

2206-2207

1 reference

Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group

7 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900307-3

7 January 2021

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900307-3

7 January 2021

The IL-2/IL-2 receptor system: a current overview

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900307-3

7 January 2021

A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900307-3

7 January 2021

Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900307-3

7 January 2021

10.1016/S0041-1345(99)00307-3

Identifiers

DOI

1 reference

7 October 2017

1 reference